Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Dogwood Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 25 | 27 | +2 |
| Shares | 1.29M | 1.30M | +14.4K (+1.1%) |
| Value | $485.7K | $307.7K | −$178.0K (−36.7%) |
New holders (4)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ergoteles LLC | 32,309 | $7.63K | 0.00% |
| Cetera Investment Advisers | 16,148 | $3.81K | 0.00% |
| Cetera Advisor Networks LLC | 14,966 | $3.53K | 0.00% |
| Citadel Advisors LLC | 5 | $1 | 0.00% |
Sold out (2)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| UBS Group AG | 41,041 | $16.0K |
| Royal Bank of Canada | 33 | $0 |